Central composite design as a powerful optimisation technique for enantioresolution of the rac-11-dihydrooracin--the principal metabolite of the potential cytostatic drug oracin.

Three types of chiral stationary phase were used to achieve chromatographic resolution of enantiomers of rac-11-dihydrooracin (DHO), the principal metabolite of a potential cytostatic drug oracin. Chiralcel OD-R as a chiral stationary phase with mobile phase comprising acetonitrile (modifier) and sodium perchlorate (buffering component) proved to be the most suitable system. Chemometric optimisation based on the Box-Wilson central composite design was employed to find the optimum resolution. The optimum factor space was defined by three parameters: temperature, modifier concentration and buffer concentration. Newly designed chromatographic response functions based on a combination of resolution R(S) and retention time of the last component eluted t(RL) were employed to evaluate the resolution with regard to quality and quantity. Optimum values predicted from those models of response surfaces were in excellent agreement with the experimental results. The chromatographic resolution of DHO enantiomers is suitable for xenobiochemical studies on stereoselectivity and stereospecificity of biotransformation enzymes.

[1]  A. Dijkstra,et al.  Evaluation and optimization of laboratory methods and analytical procedures: A survey of statistical and mathematical techniques , 1978 .

[2]  L. Skálová,et al.  The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver microsomes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11-dihydrooracin to oracin. , 2000, Enantiomer.

[3]  Michael F. Wilson,et al.  Gender‐related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers , 1999, Clinical pharmacology and therapeutics.

[4]  S. Cherkaoui,et al.  Enantioseparation of atropine by capillary electrophoresis using sulfated beta-cyclodextrin: application to a plant extract. , 2000, Journal of chromatography. A.

[5]  A. Somogyi,et al.  Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. , 2000, British journal of clinical pharmacology.

[6]  D. Boulton,et al.  The Pharmacokinetics of Levosalbutamol , 2001, Clinical Pharmacokinetics.

[7]  H. Aboul‐Enein,et al.  The Impact of Stereochemistry on Drug Development and Use , 1997 .

[8]  L. Mather,et al.  Stereoselective interaction of thiopentone enantiomers with the GABAA receptor , 1999, British journal of pharmacology.

[9]  D. Kopacz,et al.  The meningeal permeability of R- and S-bupivacaine are not different: evidence that pharmacodynamic differences between the enantiomers are not the result of differences in bioavailability. , 2000, Anesthesiology.

[10]  A. Fell,et al.  High-performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin. Interspecies comparison. , 1998, Journal of chromatography. A.

[11]  D. Massart,et al.  Rapid development of the enantiomeric separation of beta-blockers by capillary electrophoresis using an experimental design approach. , 1999, Journal of chromatography. A.

[12]  L. Skálová,et al.  A comparison between stereospecificity of oracin reduction and stereoselectivity of oxidation of 11-dihydrooracin enantiomers in vitro in rat and guinea pig. , 1999, Chirality.

[13]  Y. Daali,et al.  Experimental design for enantioselective separation of celiprolol by capillary electrophoresis using sulfated β‐cyclodextrin , 1999, Electrophoresis.

[14]  D. Smith,et al.  Pharmacokinetics and pharmacodynamics of pirmenol enantiomers in coronary artery ligated dogs. , 1997, Journal of pharmaceutical sciences.

[15]  L. Skálová,et al.  Sex differences in stereospecificity of oracin reductases in rat in vitro and in vivo. , 1999, Chirality.

[16]  D. Drayer.  Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: An overview , 1986, Clinical pharmacology and therapeutics.

[17]  A. Fell,et al.  Separation of the stereoisomers of the main metabolite of a non-steroidal anti-inflammatory drug, flobufen, by chiral high-performance liquid chromatography. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[18]  V. Dohnal,et al.  Prediction of chiral separations using a combination of experimental design and artificial neural networks. , 1999, Chirality.

[19]  H. Hirbec,et al.  Gacyclidine: a new neuroprotective agent acting at the N-methyl-D-aspartate receptor. , 2006, CNS drug reviews.

[20]  A. Fassihi,et al.  Racemates and enantiomers in drug development , 1993 .

[21]  G. Box,et al.  On the Experimental Attainment of Optimum Conditions , 1951 .

[22]  J. Berridge,et al.  Method development in liquid chromatography with a charged cyclodextrin additive for chiral resolution of rac-amlodipine utilising a central composite design. , 1996, Chirality.

[23]  B. Szotáková,et al.  High-performance liquid chromatographic assay for the separation and characterization of metabolites of the potential cytostatic drug oracine. , 1996, Journal of chromatography. B, Biomedical applications.

[24]  J. Veuthey,et al.  Central composite design in the chiral analysis of amphetamines by capillary electrophoresis , 1997, Electrophoresis.

[25]  A. Krstulović.  Chiral separations by HPLC , 1989 .

[26]  J. Berridge,et al.  Chiral recognition in liquid chromatography utilising chargeable cyclodextrins for resolution of doxazosin enantiomers. , 1997, Chirality.

[27]  John C. Berridge,et al.  Techniques for the automated optimization of HPLC separations , 1985 .